Literature DB >> 6209768

Capsular polysaccharides of Cryptococcus neoformans.

A K Bhattacharjee, J E Bennett, C P Glaudemans.   

Abstract

Polysaccharides of Cryptococcus neoformans are considered to have a role in the virulence of this encapsulated fungus. The structure has been determined for the most abundant polysaccharide, a glucuronoxylomannan of varying xylose and ester content. The structural complexity of the capsular material increases from serotype D to A to B to C, but even for the simplest capsule (type D), the immunodeterminants seem to occur only on the side chains. The interactions of some of these groups with antibodies is discussed.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6209768     DOI: 10.1093/clinids/6.5.619

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  76 in total

Review 1.  A yeast under cover: the capsule of Cryptococcus neoformans.

Authors:  Indrani Bose; Amy J Reese; Jeramia J Ory; Guilhem Janbon; Tamara L Doering
Journal:  Eukaryot Cell       Date:  2003-08

2.  Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B.

Authors:  N Mozaffarian; J W Berman; A Casadevall
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Production of agglutinating monoclonal antibody against antigen 8 specific for Cryptococcus neoformans serotype D.

Authors:  R Ikeda; S Nishimura; A Nishikawa; T Shinoda
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

4.  Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.

Authors:  Zong Liang Chang; Dale Netski; Peter Thorkildson; Thomas R Kozel
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

5.  Phenotypic heterogeneity in expression of epitopes in the Cryptococcus neoformans capsule.

Authors:  Marcellene A Gates-Hollingsworth; Thomas R Kozel
Journal:  Mol Microbiol       Date:  2009-09-02       Impact factor: 3.501

6.  Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.

Authors:  T R Kozel; B C deJong; M M Grinsell; R S MacGill; K K Wall
Journal:  Infect Immun       Date:  1998-04       Impact factor: 3.441

7.  Specificity of Cryptococcus neoformans factor sera determined by enzyme-linked immunosorbent assay and dot enzyme assay.

Authors:  T Belay; R Cherniak; T Shinoda
Journal:  Infect Immun       Date:  1993-07       Impact factor: 3.441

8.  Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells.

Authors:  S Schelenz; R Malhotra; R B Sim; U Holmskov; G J Bancroft
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

9.  Mechanisms of inhibition of Cryptococcus neoformans by human lymphocytes.

Authors:  S M Levitz; E A North; M P Dupont; T S Harrison
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

10.  Galactoxylomannans of Cryptococcus neoformans.

Authors:  P G James; R Cherniak
Journal:  Infect Immun       Date:  1992-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.